Literature DB >> 15960639

Marked variation in oxycodone pharmacokinetics in infants.

Marja-Leena Pokela1, Eija Anttila, Timo Seppälä, Klaus T Olkkola.   

Abstract

BACKGROUND: The pharmacokinetics of oxycodone (13-hydroxy-7,8-dihydrocodeinone) has been studied in adults and in children who are older than 6 months but there is no information on the disposition of oxycodone in neonates and young infants. The aim of this study was to study the pharmacokinetics of oxycodone in infants varying in age from 0 to 6 months.
METHODS: Twenty-two infants undergoing surgery were given postoperatively an intravenous bolus of 0.1 mg.kg(-1) of oxycodone hydrochloride. Ten of the patients were younger than 1 week (group 1), six from 1 week to 2 months (group 2) and six from 2 to 6 months (group 3). Plasma samples were collected for the analysis of oxycodone concentrations up to 24 h. Pharmacokinetics were characterized by noncompartmental methods.
RESULTS: The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).kg(-1) in the above three groups. The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively. Both Cl (r = 0.46) and half-life (r = -0.46) were correlated to the age of the patient (P < 0.05). There were 13 patients who were on mechanical ventilation at the time of oxycodone administration. None of the spontaneously breathing infants had hypoventilation which required assistance during the study.
CONCLUSIONS: The values for Cl and t(1/2) varied greatly between the subjects. This variability was most pronounced in the two youngest groups. Routine dosing of oxycodone in young infants may be dangerous. The dose of oxycodone must be titrated individually.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15960639     DOI: 10.1111/j.1460-9592.2005.01571.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  9 in total

1.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Oxycodone overdose in the pediatric population: case files of the University of Massachusetts Medical Toxicology Fellowship.

Authors:  Katherine L Boyle; Christopher D Rosenbaum
Journal:  J Med Toxicol       Date:  2014-09

3.  Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.

Authors:  Antti Liukas; Kristiina Kuusniemi; Riku Aantaa; Petri Virolainen; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 4.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

5.  Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.

Authors:  Merja Kokki; Marja Heikkinen; Pyry Välitalo; Heidi Hautajärvi; Juho Hokkanen; Hanna Pitkänen; Ulla Sankilampi; Veli-Pekka Ranta; Hannu Kokki
Journal:  Br J Clin Pharmacol       Date:  2016-12-05       Impact factor: 4.335

6.  Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.

Authors:  Pyry Välitalo; Merja Kokki; Veli-Pekka Ranta; Klaus T Olkkola; Andrew C Hooker; Hannu Kokki
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

Review 7.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.

Authors:  Timo Korjamo; Ari Tolonen; Veli-Pekka Ranta; Miia Turpeinen; Hannu Kokki
Journal:  Front Pharmacol       Date:  2012-01-05       Impact factor: 5.810

9.  Brain-Derived Extracellular Vesicle microRNA Signatures Associated with In Utero and Postnatal Oxycodone Exposure.

Authors:  Farah Shahjin; Rahul S Guda; Victoria L Schaal; Katherine Odegaard; Alexander Clark; Austin Gowen; Peng Xiao; Steven J Lisco; Gurudutt Pendyala; Sowmya V Yelamanchili
Journal:  Cells       Date:  2019-12-19       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.